BRPI0807897A2 - Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase. - Google Patents
Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase.Info
- Publication number
- BRPI0807897A2 BRPI0807897A2 BRPI0807897-1A2A BRPI0807897A BRPI0807897A2 BR PI0807897 A2 BRPI0807897 A2 BR PI0807897A2 BR PI0807897 A BRPI0807897 A BR PI0807897A BR PI0807897 A2 BRPI0807897 A2 BR PI0807897A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine
- kinase inhibitors
- diamine derivatives
- jak2 kinase
- jak2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89238507P | 2007-03-01 | 2007-03-01 | |
| US91177607P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/055452 WO2008106635A1 (en) | 2007-03-01 | 2008-02-29 | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0807897A2 true BRPI0807897A2 (pt) | 2014-06-17 |
Family
ID=39473235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0807897-1A2A BRPI0807897A2 (pt) | 2007-03-01 | 2008-02-29 | Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080214558A1 (pt) |
| EP (1) | EP2121634A1 (pt) |
| JP (1) | JP2010520222A (pt) |
| KR (1) | KR20090129434A (pt) |
| AU (1) | AU2008221278A1 (pt) |
| BR (1) | BRPI0807897A2 (pt) |
| CA (1) | CA2679489A1 (pt) |
| MX (1) | MX2009009117A (pt) |
| TW (1) | TW200843776A (pt) |
| WO (1) | WO2008106635A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2150545A1 (en) * | 2007-04-27 | 2010-02-10 | AstraZeneca AB | N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions |
| WO2010011349A2 (en) * | 2008-07-25 | 2010-01-28 | Supergen, Inc. | Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use |
| CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| ES2738493T3 (es) * | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | Inhibidores de JAK2 y ALK2 y métodos para su uso |
| WO2016172214A1 (en) | 2015-04-20 | 2016-10-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
| US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
| CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| CA3103995A1 (en) * | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| CN115029299B (zh) * | 2018-11-07 | 2023-11-14 | 杭州瑞普晨创科技有限公司 | JAK2抑制剂在胰岛β细胞诱导分化中的应用 |
| EP3890749A4 (en) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| MXPA06003054A (es) * | 2003-09-18 | 2006-05-31 | Novartis Ag | 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos. |
| US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| RU2597364C2 (ru) * | 2005-11-01 | 2016-09-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
| CA2642229C (en) * | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US7834024B2 (en) * | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
-
2008
- 2008-02-29 US US12/040,002 patent/US20080214558A1/en not_active Abandoned
- 2008-02-29 AU AU2008221278A patent/AU2008221278A1/en not_active Abandoned
- 2008-02-29 EP EP08754838A patent/EP2121634A1/en not_active Withdrawn
- 2008-02-29 WO PCT/US2008/055452 patent/WO2008106635A1/en active Application Filing
- 2008-02-29 TW TW097107249A patent/TW200843776A/zh unknown
- 2008-02-29 KR KR1020097019702A patent/KR20090129434A/ko not_active Application Discontinuation
- 2008-02-29 CA CA002679489A patent/CA2679489A1/en not_active Abandoned
- 2008-02-29 JP JP2009551869A patent/JP2010520222A/ja not_active Withdrawn
- 2008-02-29 BR BRPI0807897-1A2A patent/BRPI0807897A2/pt not_active Application Discontinuation
- 2008-02-29 MX MX2009009117A patent/MX2009009117A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010520222A (ja) | 2010-06-10 |
| US20080214558A1 (en) | 2008-09-04 |
| EP2121634A1 (en) | 2009-11-25 |
| KR20090129434A (ko) | 2009-12-16 |
| MX2009009117A (es) | 2009-09-03 |
| CA2679489A1 (en) | 2008-09-04 |
| WO2008106635A1 (en) | 2008-09-04 |
| AU2008221278A1 (en) | 2008-09-04 |
| TW200843776A (en) | 2008-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0807897A2 (pt) | Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase. | |
| CU23886B1 (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b | |
| BRPI0811434A2 (pt) | imidazopiridazinas como inibidores de pi3k lipídeo cinase. | |
| BRPI0908433A2 (pt) | pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase | |
| BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
| BRPI0812893A2 (pt) | Derivados de quinoxalina como inibidores da atividade de tirosina quinase de janus quinases | |
| AP2012006166A0 (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors. | |
| BRPI0809998A2 (pt) | Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase | |
| BRPI1016150A2 (pt) | compostos heterocíclicos e seus usos. | |
| HRP20130796T1 (en) | Pyrimidine derivatives used as pi-3 kinase inhibitors | |
| DK1761505T3 (da) | Pyrimidin-urinstof-derivater som kinaseinhibitorer | |
| NL2000323A1 (nl) | Pyrimidine-derivaten. | |
| ATE541850T1 (de) | Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel | |
| BRPI0922095A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| HK1187895A1 (zh) | 嘧啶衍生物用作蛋白激酶抑制劑 | |
| ZA201100344B (en) | Pyrimidine derivatives as kinase inhibitors | |
| NO20091423L (no) | Pyrimidinderivater og deres anvendelse som kinaseinhibitorer | |
| BR112012002110A2 (pt) | derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase | |
| IL202835A0 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
| BRPI0921598A2 (pt) | derivados de piridina e pirimidina como inibidores de fosfodiesterase 10 | |
| BRPI0810858A2 (pt) | Derivados de 2-heteroaril-pirrolo[3,4-c] pirrol e seus usos como inibidores de scd | |
| BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
| BRPI0812865A2 (pt) | Derivados de 6-anilinopurina substituída como inibidores de citoquinina oxidase/desidrogenase e preparações contendo esses derivados. | |
| ES2465673T9 (es) | Derivados de pirimidina | |
| EP2178375A4 (en) | DERIVATIVES OF PYRAZOLOÝ1,5-A¨PYRIMIDINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |